SRR5903550
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- INTERFERON_ALPHA_RESPONSE+0.490
- MTORC1_SIGNALING+0.440
- INTERFERON_GAMMA_RESPONSE+0.420
- ANDROGEN_RESPONSE+0.400
- MYC_TARGETS_V2+0.380
- TNFA_SIGNALING_VIA_NFKB+0.370
- GLYCOLYSIS+0.360
- KRAS_SIGNALING_UP+0.360
- MYC_TARGETS_V1+0.360
Top 10 suppressed
- MYOGENESIS-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- WNT_BETA_CATENIN_SIGNALING-0.240
- APICAL_JUNCTION-0.170
- HEDGEHOG_SIGNALING-0.150
- UV_RESPONSE_DN-0.090
- APICAL_SURFACE-0.080
- KRAS_SIGNALING_DN-0.060
- ANGIOGENESIS-0.020
- DNA_REPAIR-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313147 | — | E | 0.885 |
| 2 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.875 |
| 3 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.865 |
| 4 | SRR6013490 | — | cohortA4 | 0.854 |
| 5 | BS_X59HSFGG | low-grade glioma | — | 0.853 |
| 6 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.852 |
| 7 | SRR12696807 | — | — | 0.850 |
| 8 | BS_GJNCYABP | ATRT | — | 0.850 |
| 9 | DRR168585 | — | — | 0.850 |
| 10 | TCGA-22-1017-01A-01R-0692-07 | — | cohortA1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |